Beth DiSanzo

Statistics

Publications

Citations

1.1K

H-Index

Active since

2011

Affiliations

Alexion Pharmaceuticals (United States)(Current)

University at Buffalo, State University of New York

Fondazione IRCCS Istituto Neurologico Carlo Besta

National Hospital Organization Hanamaki Hospital

University of Massachusetts Boston

Beth DiSanzo is an author at Alexion Pharmaceuticals (United States) specializing in medicine, myasthenia gravis pharmacotherapy, and pharmacotherapy.

Publications per year

2011–2020

Publications

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 800 citations

Medicine, Pharmacology, Pharmacotherapy +6

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

Renato Mantegazza, Gil I. Wolfe, Srikanth Muppidi et al. · Neurology · 2020 · 79 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +9

Adipose tissue endocannabinoid system gene expression: depot differences and effects of diet and exercise

Tongjian You, Beth DiSanzo, Xuewen Wang et al. · Lipids in Health and Disease · 2011 · 59 citations · Full text

Life Sciences, Biochemistry, Nutritional Sciences +15

Eculizumab improves fatigue in refractory generalized myasthenia gravis

Henning Andersen, Renato Mantegazza, Jing Jing Wang et al. · Quality of Life Research · 2019 · 56 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Effects of exercise training on indicators of adipose tissue angiogenesis and hypoxia in obese rats

Beth DiSanzo, Tongjian You · Metabolism · 2013 · 43 citations

Life Sciences, Physiology, Exercise Physiology +15

1–5 of 9